Evidence map›Paper›PMID 23467779›Full record

ArticleCellular and molecular neurobiology2013

Methadone-induced hypoglycemia.

Andrew J Faskowitz, Vladimir N Kramskiy, Gavril W Pasternak

Abstract read
In one paragraph

Article in Cellular and molecular neurobiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Methadone-induced hypoglycemia: A case report.Journal of diabetes investigation · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Hypoglycaemia without diabetes encountered by emergency medical services: a retrospective cohort study.Scandinavian journal of trauma, resuscitation and emergency medicine · 2018
    Article
  13. Article
  14. Review
  15. Article
  16. Observational
  17. Article
  18. Opiate pharmacology and relief of pain.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Andrew J FaskowitzDepartment of Neurology and The Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA.
Vladimir N Kramskiy
Gavril W Pasternak
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
TRAINING IN BEHAV. PHARMACOLOGY OF HUMAN DRUG DEPENDENCET32DA007242 · NIDA · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI HEIL, SARAH H, HIGGINS, STEPHEN T · 1990 to 2025
$8.2M
Synthesis &Pharmacology of Novel Opiates and SystemsR01DA006241 · NIDA · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PAN, YING-XIAN · 1990 to 2018
$6.4M
PHARMACOLOGY OF OPIOID RECEPTOR SUBTYPESR01DA007242 · NIDA · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PAN, YING-XIAN · 1991 to 2022
$6.0M
Biochemical Characterization of Opioid ReceptorsR01DA002615 · NIDA · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PASTERNAK, GAVRIL W · 1985 to 2010
$4.9M
PHARMACOLOGY OF OPIOID RECEPTOR SUBTYPESR37DA007242 · NIDA · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PASTERNAK, GAVRIL W · 1996 to 2004
$1.5M
Biochemical Characterization of Opioid BInding SitesR56DA002615 · NIDA · SLOAN-KETTERING INST CAN RESEARCH · PI PASTERNAK, GAVRIL W · 2012 to 2013
$1.1M
OPIATE RECEPTOR PHARMACOLOGYK05DA000220 · NIDA · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PASTERNAK, GAVRIL W · 1994 to 2008
$1.1M
NCI NIH HHS CA08748NCI NIH HHS P30 CA008748NIDA NIH HHS DA00220NIDA NIH HHS DA02615NIDA NIH HHS DA07242NIDA NIH HHS K05 DA000220NIDA NIH HHS R01 DA002615NIDA NIH HHS R01 DA006241NIDA NIH HHS R01 DA007242NIDA NIH HHS R37 DA007242NIDA NIH HHS R56 DA002615NIDA NIH HHS T32 DA007242
6 · The paper itself

Abstract

To determine if recent observations of hypoglycemia in patients receiving high-dose methadone extended to an animal model, we explored the effects of methadone and other mu-opioids on blood glucose levels in mice. Methadone lowered blood glucose in a dose-dependent manner with 20 mg/kg yielding a nadir in average glucose levels to 55 ± 6 mg/dL from a baseline of 172 ± 7 mg/dL, an effect that was antagonized by naloxone and mu selective antagonists β-funaltrexamine and naloxonazine. The effect was stereoselective and limited to only the l-isomer, while the d-isomer was ineffective. Despite the robust decrease in blood glucose produced by methadone, a series of other mu-opioids, including morphine, fentanyl, levorphanol, oxycodone or morphine-6β-glucuronide failed to lower blood glucose levels. Similar differences among mu-opioid agonists have been observed in other systems, suggesting the possible role of selected splice variants of the mu-opioid receptor gene Oprm1. This mouse model recapitulates our clinical observations and emphasizes the need to carefully monitor glucose levels when using high methadone doses, particularly intravenously, and the need for controlled clinical trials.

Indexed as

Analgesics, OpioidAnimalsBlood GlucoseDose-Response Relationship, DrugExonsHypoglycemiaMaleMethadoneMiceMice, KnockoutReceptors, Opioid, muTime FactorsAnalgesics, OpioidBlood GlucoseMethadoneReceptors, Opioid, mu

Identifiers

PMID23467779
PMCPMC3622167
OpenAlexW2006653172

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.